| Similar Articles |
|---|
 |
The Motley Fool
June 6, 2007
Tim Beyers |
Who's Buying Now? Sometimes, insiders are buying for all the right reasons. Who's at it this week? Brookdale Senior Living... Genomic Health... Green Plains Renewable Energy... Sunesis Pharmaceuticals... etc.   |
The Motley Fool
March 28, 2007
Tim Beyers |
Who's Buying Now? Sometimes insiders are buying for all the right reasons. Who's at it this week? Chesapeake Energy... Hawk Corp... IndyMac Bancorp... Owens Corning... U-Store-It Trust... |
The Motley Fool
October 18, 2006
Tim Beyers |
Who's Buying Now? Sometimes insiders are buying for all the right reasons. Who's at it this week? Cantel Medical... NeoPharm... Star Buffet... |
The Motley Fool
May 8, 2007
Brian Lawler |
Unstoppable Celgene The biotech powerhouse continues its strong financial results as Revlimid sales grow. |
The Motley Fool
December 26, 2007
Tim Beyers |
Who's Buying Now? Insider purchases: General Growth Properties...Isle of Capri Casinos... NCI Building Systems... Resources Connection... Universal Forest Products... |
The Motley Fool
November 1, 2006
Tim Beyers |
Who's Buying Now? Sometimes insiders are buying for all the right reasons. Who's at it this week? Art Technology Group... Home Bancshares... Sigmatel... Sturm, Ruger & Co... etc. |
The Motley Fool
July 24, 2008
Tim Beyers |
Who's Buying Now? Insider purchases: Flagstar Bancorp... Marriott International... U.S. Bancorp... ValueClick... Wachovia... |
The Motley Fool
May 2, 2007
Tim Beyers |
Who's Buying Now? Sometimes insiders are buying for all the right reasons. Who's at it this week? Capitol Bancorp... Pentair... Popular... Parker-Hannifin... Security Bank Corp... etc. |
The Motley Fool
May 8, 2009
Tim Beyers |
Stocks the Rich Executives Are Buying Sometimes insiders are buying for all the right reasons. Who's at it this week? Insiders are buying at: Kinder Morgan Management... St. Jude Medical... Verizon... |
The Motley Fool
December 27, 2006
Tim Beyers |
Who's Buying Now? Sometimes, insiders are buying for all the right reasons. Who's at it this week? Emeritus... Enterprise Products Partners... Equity One... Penn Treaty American... etc. |
The Motley Fool
April 30, 2009
Tim Beyers |
Stocks the Rich Executives Are Buying Sometimes insiders are buying for all the right reasons. Who's at it this week? |
The Motley Fool
January 11, 2010
Brian Orelli |
Celgene Revs Up for a New Year Preliminary 2009 sales released at the J.P. Morgan Health Care Conference have sales up about 20% year over year and Celgene is guiding for 20% revenue growth next year as well. |
The Motley Fool
June 4, 2008
Tim Beyers |
Who's Buying Now? Insider buying: Checkpoint Systems... Chesapeake Energy... General Electric... Valeant Pharmaceuticals... Virtual Radiologic... |
The Motley Fool
January 21, 2009
Tim Beyers |
Stocks the Rich Executives Are Buying Sometimes insiders are buying for all the right reasons. Who's at it this week? Take a look at insider buying at these companies: A. Schulman... Greenbrier Companies... Oracle... Stericycle... Worthington Industries... |
The Motley Fool
February 6, 2007
Brian Lawler |
Celgene Mints the Green Stuff Biotech firm Celgene reports its 2006 financial results and provides an update for its 2007 guidance. Biopharma investors know it's not the past that matters the most in this sector; it's the outlook. |
The Motley Fool
June 8, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Is Celgene the new Genentech? Maybe not -- but it's cheap. |
The Motley Fool
July 29, 2010
Brian Orelli |
This Best Biotech Is Cheaper Than You Think The cancer-drug specialist justifies its valuation quite effectively with a stellar second-quarter performance. |
The Motley Fool
October 23, 2009
Brian Orelli |
Not 50% Growth, but We'll Take It Double-digit growth is still pretty good for Celgene. |
The Motley Fool
December 16, 2008
Tim Beyers |
Sell Oracle? Bah! Humbug! Oracle reports earnings this Thursday, and Wall Street isn't expecting good news. But there's still much to like about this company. |
The Motley Fool
October 30, 2006
Brian Lawler |
Celgene: Drug Kingpin Trading at 129 times trailing-12-month adjusted earnings, the biopharmaceutical looks ridiculously expensive, until one considers its awesome sales and earnings growth in that time period. Investors, take note. |
The Motley Fool
January 30, 2009
Brian Orelli |
Celgene's Double Take Still Looks Good No one is going to stop using Celgene's cancer-fighting products just because the economy is in the tank, so the company should have no problem hitting or even exceeding its growth estimates the way it has before. |
The Motley Fool
November 15, 2011
Alexander Crawford |
5 Insider Stock Picks that Predictive Analysts Expect to Outperform Do you think these stocks are in a strong position to move higher? |
The Motley Fool
September 9, 2009
Tim Beyers |
Should You Sell Everything Now? Insider selling has reached levels not seen in a while. |
The Motley Fool
January 13, 2009
Brian Orelli |
Celgene's Still Surging With returns over the last five years that just about any investor would love to have, it might be fair to wonder whether Celgene can keep it up. It seems it can. |
The Motley Fool
November 20, 2007
Brian Orelli |
Celgene Buys a Sales Force Pharmaceutical Celgene acquires Pharmion for $2.9 billion, hoping that Pharmion's two drugs in mid-to-late clinical trials will justify the purchase price in the not-too-distant future. |
The Motley Fool
April 28, 2011
Brian Orelli |
Celgene Gets No Love The market shrugs off a solid quarter. |
The Motley Fool
February 16, 2007
Brian Lawler |
The Biotech Academy Awards Investors, here are some biotech Oscars for last year's performances: The Biotech Best Picture award -- Celgene... The Biotech Best Drama -- Elan and BiogenIdec... etc. |
The Motley Fool
April 30, 2010
Brian Orelli |
New CEO, Same Old Double-Digit Increases Another strong quarter from Celgene. |
The Motley Fool
January 29, 2010
Brian Orelli |
Wake Up! You Still Have to Pay Attention We already knew Celgene's preliminary numbers, but the conference call offers a look ahead. |
The Motley Fool
January 22, 2009
Dave Mock |
3 Reasons to Buy Microsoft Today There are others, but here are three big reasons to buy Microsoft today: it's a cash machine with an innovative future at a discount. Read on for more. |
The Motley Fool
October 6, 2010
Brian Orelli |
Celgene Is All Grown Up An acquirer is on the prowl. |
The Motley Fool
March 23, 2005
John Reeves |
Stock Madness 2005: Lloyds TSB vs. Celgene Backgrounds on two stocks you might want to consider: Lloyds and Celgene. |
The Motley Fool
March 30, 2005
Charly Travers |
Stock Madness 2005: Celgene vs. Netflix Biotech battles entertainment in this Round 3 matchup of "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness. |
The Motley Fool
March 31, 2009
Brian Orelli |
5 Highly Rated Stocks in the Red The price to earnings ratio (P/E) has to be one of the most overused valuation tools in history. But earnings aren't all they're cracked up to be. Read on to see why. |
The Motley Fool
December 7, 2009
Brian Orelli |
When the Big Guns Come In, You Get Blasted Larger drug companies may want to gobble up smaller drug firms like Allos Therapeutics and Gloucester Pharmaceuticals. |
The Motley Fool
July 31, 2008
Dan Dzombak |
3 Stocks Hitting High Notes These stocks are bucking the trend and hit new highs. Take a look at: Terra Industries... Flowserve... Celgene... |
Chemistry World
July 8, 2015
Phillip Broadwith |
Celgene backs immunotherapy with Juno collaboration US biopharmaceutical firm Celgene is to bolster its position in the emerging field of cell therapy through a collaboration with biotech Juno Therapeutics. |
The Motley Fool
August 29, 2011
Anders Bylund |
Noah Holdings Shares Got Temporarily Crushed: What You Need to Know Shares of China-based wealth management specialist Noah Holdings crashed in intraday trading to an 11.9% drop at worst, then rebounded to a 6.8% gain at the top and now trade roughly where they were after Friday's closing bell. |
The Motley Fool
January 28, 2011
Brian Orelli |
Celgene Needs a Rocket Ship Celgene really needs a hit from Abraxane and other drugs it may license or purchase. |
The Motley Fool
March 21, 2005
Alyce Lomax |
Stock Madness 2005: Dell vs. Celgene The computer maker and the biotech company vie for a berth in the next round of "Stock Madness 2005," a contest based loosely on the annual NCAA College Basketball Tournament, a.k.a. March Madness. |
The Motley Fool
January 31, 2008
Brian Lawler |
Prioritizing Millennium The FDA grants a speedy review for Millennium Pharmaceuticals's lead multiple myeloma drug. |
